Article Text

other Versions

PDF
Effects of 12 weeks of atorvastatin therapy on myocardial fibrosis and circulating fibrosis biomarkers in statin-naïve patients with hypertension with atherosclerosis
  1. Yi-Yao Chang1,
  2. Yen-Wen Wu1,2,3,
  3. Jen-Kuang Lee2,
  4. Yu-Min Lin4,
  5. Yen-Ting Lin5,
  6. Hsian-Li Kao2,
  7. Chi-Sheng Hung2,
  8. Hung-Ju Lin2,
  9. Yen-Hung Lin2
  1. 1Division of Cardiology, Cardiovascular Medical Center, Far Eastern Memorial Hospital, New Taipei City, Taiwan
  2. 2Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
  3. 3National Yang-Ming University, School of Medicine, Taipei, Taiwan
  4. 4Department of Medical Image, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
  5. 5Department of Internal Medicine, Taoyuan General Hospital, Taoyuan, Taiwan
  1. Correspondence to Dr Yen-Hung Lin, Division of Cardiology, Department of Internal Medicine, National Taiwan University Hospital, 7 Chung-Shan South Road, Taipei 10001, Taiwan; austinr34{at}gmail.com

Abstract

The purpose of this study was to assess the effects of 12 weeks of atorvastatin treatment on myocardial fibrosis in patients with hypertension with atherosclerosis. 15 statin-naïve participants (11 males; mean age 67±10 years) with atherosclerosis were given atorvastatin (40 mg/day) for 12 weeks and underwent echocardiography including ultrasonic tissue characterization by cyclic variation of integrated backscatter (CVIBS). Serum galectin-3 and fibrosis markers including aminoterminal propeptide of type III procollagen (PIIINP), matrix metalloproteinase-2, metalloproteinase-9, and tissue inhibitor of metalloproteinase-1 (TIMP-1) were also analyzed. After 12 weeks of atorvastatin (40 mg/day) treatment, serum total cholesterol and low-density lipoprotein cholesterol decreased significantly (204±31 to 140±24 mg/dL and 133±26 to 69±17 ng/mL, respectively, both p<0.001). In myocardial fibrosis analysis, CVIBS increased significantly (6.6±1.9 to 8.5±2.7 dB, p=0.024). In addition, the circulating fibrosis markers serum PIIINP and TIMP-1 decreased significantly (9.5±2.7 to 6.4±1.4 ng/mL, p=0.012 and 299±65 to 250±45 ng/mL, p=0.024, respectively). 12 weeks of medium dose atorvastatin treatment resulted in a significant reduction in myocardial fibrosis as evaluated by morphofunctional parameters and plasma markers of tissue fibrosis.

Trial registration number NTC00172419; results.

  • Cardiovascular Diseases
  • Cholesterol
  • Atherosclerosis
  • Cardiology

Statistics from Altmetric.com

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.